PA317产生高滴度带有人TNF-α基因逆转录病毒的研究

Study on PA317 Producing High Titers of Retroviral Vector Inserted with Human TNF-αGene

逆转录病毒介导的基因转移技术要过渡到临床应用,主要解决如何使病毒载体具有高滴度而不具有复制活性。本文旨在探索建立一种合适的方法,能产生高滴度而且是安全的逆转录病毒载体。采用带有人肿瘤坏死因子基因的LXSN载体转染PA317包装细胞,建立产病毒的包装细胞株,结果表明:病毒载体滴度受包装培养液体积和胎牛血清浓度影响;包装细胞在32℃产生的病毒滴度比37℃高,而且比较稳定。产病毒包装细胞和被感染的靶细胞经PCR分析显示,被转染和被转导的细胞都有病毒基因的整合,而且包装细胞不会产生具有复制活性的逆转录病毒,因此能进一步用于临床研究。

In order to use retroviral-mediated gene transfer technology in clinical application, retroviral vector must be of high titer and free of detectable replication-competent retroviruses (RCR). The aim of this study was to optimize methods of defective retroviral vector production. Study was conducted using a LXSN vector inserted with human tumor necrosis factor-α gene and an amphotropic retrovirus packaging cell line-PA317. The results indicated that viral titer was influenced by volume of medium and concentration of fetal calf serum. Inactivation of retroviral vector was greater at 37癈 than at 32癈. In experiment of transfection of PA317 and transduction of 3T3, integration of retroviral vector into genome of packaging cells and target cells, and free of RCR were detected by polymerase chain reaction analysis. Viral vector with high titer and free of RCR is able to use in clinical trial